Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 9/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712795 | 0.77 | S1PR1 (0.34) | CYP11B1CYP11B2EPAS1KIF11TAS2R14 | |
| SCHEMBL31235049 | 0.77 | KIF11 (0.37) | CYP11B1CYP11B2EPAS1KIF11TAS2R14 | |
| SCHEMBL19865216 | 0.77 | KIF11 (0.41) | CYP11B1CYP11B2EPAS1KIF11KDM1A | |
| SCHEMBL6703882 | 0.77 | KIF11 (0.41) | CYP11B1CYP11B2EPAS1KIF11KDM1A | |
| SCHEMBL5733956 | 0.77 | CYP11B1 (0.35) | CYP11B1CYP11B2EPAS1KIF11KDM1A | |
| SCHEMBL30524326 | 0.77 | PDE2A (0.40) | CYP11B1CYP11B2KIF11KDM1AHSD11B1 | |
| SCHEMBL8160495 | 0.77 | PDE2A (0.40) | CYP11B1CYP11B2KIF11KDM1AHSD11B1 | |
| SCHEMBL29487566 | 0.73 | CES2 (0.36) | — | |
| SCHEMBL313506 | 0.73 | CES2 (0.36) | — | |
| SCHEMBL5733013 | 0.73 | CYP11B1 (0.35) | CYP11B1CYP11B2EPAS1KIF11KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981930-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200385399-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-10 | — | — | US | disclosed |
| JP-2004059521-A | METHOD FOR PRODUCING 2,3-DIFLUORO-6-TRIFLUOROMETHYLBENZONITRILE | ASAHI GLASS CO LTD | 2004-02-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981930-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OR51E2, EPCAM | CYP11B1 859/4885CYP11B2 409/4885EPAS1 3905/4885 |
| US-20200385399-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, OR51E2, EPCAM | CYP11B1 859/4885CYP11B2 409/4885EPAS1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.